STAT+: Novo Nordisk\u2019s $199 Ozempic deal shows what telehealth platforms can do for pharma
\n \t
\n
<\/BR>
\n
\n \t
\n
<\/BR><\/p>\n
On Monday, Novo Nordisk announced a discount on its popular drugs for diabetes and obesity, Ozempic and Wegovy, cutting prices for the lowest doses to $199 when patients pay cash through Novo\u2019s pharmacy NovoCare.\u00a0<\/p>\n
Patients searching for those deals online, though, won\u2019t always get funneled to the drugmaker\u2019s sites. Instead, the first results they may see are ads from telehealth companies that partner with Novo Nordisk.\u00a0<\/p>\n
Sponsored Google search results from LifeMD and WeightWatchers touting the temporary $199 discount \u2014 \u201cFinally afford a GLP-1\u201d \u2014 can appear before links to Novo Nordisk\u2019s own sites. Telehealth companies can springboard off of consumer interest in drugmaker deals to drive patients to their platforms. On Monday, prescription drug discount platform GoodRx also used the opportunity to launch a new telehealth weight loss subscription.\u00a0<\/p>\n
Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n